Get startedLog in
    Picture of Evoke Pharma logo

    EVOK — Evoke Pharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    Evoke Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

    Picture of Evoke Pharma logoEvoke Pharma
    13/05/2025 21:59
    Evoke Pharma Inc EVOK.OQ reported a quarterly adjusted loss of 51 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.04.  The lone analyst forecast for the quarter was for a loss of 33 cents per share.

Revenue rose 77.5% to $3.08 million from a year ago; analysts expected $3.32 million.

Evoke Pharma Inc's reported EPS for the quarter was a loss of 51 cents​.

The company reported a quarterly loss of $1.31 million.

Evoke Pharma Inc shares had risen by 14.7% this quarter and lost 28.6% so far this year.

FORECAST CHANGES

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Evoke Pharma Inc is $18.00

This summary was machine generated from LSEG data May 13 at 08:59 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)


    QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
    Mar. 31 2025-0.33-0.51Missed
    Dec. 31 2024-0.63-0.63Met
    Sep. 30 2024-0.38-0.94Missed
    Jun. 30 2024-0.72-0.93Missed

    Recent news on Evoke Pharma

    See all news